NORTH CHICAGO, Ill., May 27, 2022 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced The Lancet published results from three pivotal Phase 3 clinical trials – ADVANCE, MOTIVATE (induction studies) and FORTIFY (maintenance study) – evaluating risankizumab (SKYRIZI®) in patients with moderately to severely active Crohn’s disease who have had inadequate response, lost response or were intolerant to conventional or biologic therapy.

Original Source


Notice: ob_end_flush(): failed to send buffer of zlib output compression (0) in /home/biznews/public_html/wp-includes/functions.php on line 5219